Pedmarqsi Europska Unija - hrvatski - EMA (European Medicines Agency)

pedmarqsi

fennec pharmaceuticals (eu) limited - sodium thiosulfate - ear diseases; ototoxicity - svi ostali terapeutski proizvodi - pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Vantavo (previously Alendronate sodium and colecalciferol, MSD) Europska Unija - hrvatski - EMA (European Medicines Agency)

vantavo (previously alendronate sodium and colecalciferol, msd)

n.v. organon - alendronic kiseline, colecalciferol - osteoporoza, postmenopauzalna - lijekovi za liječenje bolesti kostiju - liječenje osteoporoze u postmenopauzi u bolesnika s rizikom od insuficijencije vitamina d. vantavo smanjuje rizik od prijeloma kralježnice i kukova . liječenje постменопаузального osteoporoze kod bolesnika koji ne primaju vitamina d prehrani i rizika vitamina d bubrega. vantavo smanjuje rizik od prijeloma kralježnice i kukova .

Triumeq Europska Unija - hrvatski - EMA (European Medicines Agency)

triumeq

viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults,  adolescents and children  weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.

Convenia Europska Unija - hrvatski - EMA (European Medicines Agency)

convenia

zoetis belgium sa - cefovecin (as sodium salt) - antibakterijska sredstva za sistemsku uporabu - dogs; cats - dogsfor liječenje kože i mekih tkiva, infekcije, uključujući i gangrenosum, rane i čireve, povezane s pseudintermedius aureus, β-гемолитический strep, escherichia coli i / ili pasteurella multocida. za liječenje infekcija mokraćnog trakta povezane s escherichia coli i / ili proteus spp. kao pomoćni tretman mehaničkoj ili kirurškoj parodontnoj terapiji u liječenju teških infekcija gingive i parodontnih tkiva povezanih s porphyromonas spp. i prevotella spp. catsfor liječenje kože i mekih tkiva, čireve i rane vezane uz bakterija pasteurella multocida, usobacterium cse. , bacteroides spp. , prevotella oralis, β-hemolitički streptokoki i / ili staphylococcus pseudintermedius. za liječenje infekcija mokraćnog trakta povezane s escherichia coli.

Sugammadex Mylan Europska Unija - hrvatski - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Amomed Europska Unija - hrvatski - EMA (European Medicines Agency)

sugammadex amomed

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - uklanjanje neuromuskularne blokade izazvane rokoronom ili vekuronomom. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Adroiq Europska Unija - hrvatski - EMA (European Medicines Agency)

sugammadex adroiq

extrovis eu ltd. - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Fresenius Kabi Europska Unija - hrvatski - EMA (European Medicines Agency)

sugammadex fresenius kabi

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuskularna blokada - svi ostali terapeutski proizvodi - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Piramal Europska Unija - hrvatski - EMA (European Medicines Agency)

sugammadex piramal

piramal critical care b.v. - sugammadex sodium - neuromuskularna blokada - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Quadramet Europska Unija - hrvatski - EMA (European Medicines Agency)

quadramet

cis bio international - samarium (153sm) lexidronam pentasodium - pain; cancer - terapeutski radiofarmaceutski pripravci - quadramet je indiciran za olakšanje koštana bol u bolesnika s više bolno u tu svrhu koštanih metastaza koje zauzimaju tehnecij [99mtc]-s natpisom biphosphonates na kost skeniranja. dostupnost остеобластические metastaza, koje zauzimaju технеция [99мтс]-za označene biphosphonates mora biti potvrđena prije početka terapije.